This antibody is prepared by Saturated Ammonium Sulfate (SAS) precipitation followed by dialysis
Immunogen
This Ketohexokinase (KHK) antibody is generated from rabbits immunized with a KLH conjugated synthetic peptide between 18-46 amino acids from the N-terminal region of human Ketohexokinase (KHK).
KHK
Reactivity: Human
WB, ELISA
Host: Mouse
Monoclonal
2B1
unconjugated
Application Notes
For WB starting dilution is: 1:1000
Restrictions
For Research Use only
Format
Liquid
Concentration
2 mg/mL
Buffer
Supplied in PBS with 0.09 % (W/V) sodium azide.
Preservative
Sodium azide
Precaution of Use
This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
Storage
4 °C,-20 °C
Storage Comment
Store at 4°C for three months and -20°C, stable for up to one year. As with all antibodies care should be taken to avoid repeated freeze thaw cycles. Antibodies should not be exposed to prolonged high temperatures.
Ketohexokinase (KHK), or fructokinase, catalyzes conversion of fructose to fructose-1-phosphate. Splice variant 1 is the highly active form found in liver, renal cortex, and small intestine, while splice variant 2 is the lower activity form found in most other tissues. KHK, like glucokinase (GCK) and glucokinase regulator (GCKR), is present in both liver and pancreatic islets. The inhibition of GCK by GCKR is blocked by binding of fructose-1-phosphate to GCKR. The chromosomal proximity of the metabolically connected GCKR and KHK genes has a genetic linkage in type 2 diabetes. Fructosuria, or hepatic fructokinase deficiency, is a benign, asymptomatic defect of intermediary metabolism associated with heterozygosity for G50R and A43T mutations in KHK.